臨床泌尿器科61巻3号

2007年03月発行

綜説

Thymidine phosphorylaseを介するフッ化ピリミジン系抗癌剤のbiochemical modulation

著者： 森田辰男¹

所属機関： ¹自治医科大学医学部腎泌尿器外科学講座

ページ範囲：P.187 - P.197

要旨　Thymidine phosphorylase（TP）は，核酸代謝，血管新生，アポトーシス，腫瘍の浸潤・転移に関与するとともに，フッ化ピリミジン系抗癌剤の代謝にも関与する重要な酵素である。多くの悪性腫瘍では，隣接する非腫瘍組織と比較して腫瘍組織におけるTP発現が亢進している。また，腫瘍組織におけるTP発現が亢進している症例は，TP発現が亢進していない症例より予後不良であることが多くの悪性腫瘍で示されている。本稿では，TPを介するフッ化ピリミジン系抗癌剤のbiochemical modulationに関してTPの臨床病理学的意義も含めて泌尿器癌を中心に概説した。

参考文献

1）Heidelberger C, Chaudhuri NK, Danneberg P, et al：Fluorinated pyrimidine, a new class of tumor-inhibitory compounds. Nature 179：663-666, 1957

2）Liu G, Franssen E, Fitch M, et al：Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15：110-115, 1997

3）Sotos GA, Grogan L and Allegra CJ：Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 20：11-49, 1994

4）Furukawa T, Yoshimura A, Sumizawa T, et al：Angiogenic factor. Nature 356：668, 1992

5）Moghaddam A and Bicknell R：Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 31：12141-12146, 1992

6）Usuki K, Sarah J, Walterberger J, et al：Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun 184：1311-1316, 1992

7）Walter MR, Cook WJ, Cole LB, et al：Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 A resolution. J Biochem Chemist 265：14016-14022, 1990

8）Takebayashi Y, Yamada K, Miyadera K, et al：The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A：1227-1232, 1996

9）Yoshimura A, Kuwazuru Y, Furukawa T, et al：Purification and tissue distribution of human thymidine phosphorylase；high expression in lymphocytes, reticulocytes and tumors. Bochem Biophy Acta 1034：107-113, 1990

10）Fox SB, Moghaddam A, Westwood M, et al：Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues：an immunohistochemical study. J Pathol 176：183-190, 1995

11）Morita T, Matsuzaki A and Tokue A：Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma. Oncology 65：125-131, 2003

12）Imazono Y, Takebayashi Y, Nishiyama K, et al：Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 15：2570-2578, 1997

13）Suzuki K, Morita T, Hashimoto S, et al：Thymidine phosphorylase/platelet-derived endothelial cell growth factor（PD-ECGF）associated with prognosis in renal cell carcinoma. Urol Res 29：7-12, 2001

14）O'Brien T, Cranston D, Fuggle S, et al：Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55：510-513, 1995

15）O'Brien TS, Fox SB, Dickinson AJ, et al：Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 56：4799-4804, 1996

16）Mizutani Y, Okada Y and Yoshida O：Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 79：1190-1194, 1997

17）Kubota Y, Miura T, Moriyama M, et al：Thymidine phosphorylase activity in human bladder cancer：difference between superficial and invasive cancer. Clin Cancer Res 3：973-976, 1997

18）Sawase K, Nomata K, Kanetake H, et al：The expression of platelet-derived endothelial cell growth factor in human bladder cancer. Cancer Letters 130：35-41, 1998

19）Tanaka T, Yoshiki T, Arai Y, et al：Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human bladder cancer. Jpn J Cancer Res 90：1344-1350, 1999

20）Arima J, Imazono Y, Takebayashi Y, et al：Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 88：1131-1138, 2000

21）Sugamoto T, Tanji N, Nishio S, et al：Expression of platelet-derived endothelial cell growth factor in prostatic adenocarcinoma. Oncol Rep 6：519-522, 1999

22）Fujimoto J, Sakaguchi H, Ichigo S, et al：Expression of platelet-derived endothelial cell growth factor（PD-ECGF）and its mRNA in uterine cervical cancers. Brit J Cancer 79：1249-1254, 1999

23）Takebayashi Y, Natsugoe S, Baba M, et al：Thymidine phosphorylase in human esophageal squamous cell carcinoma. Cancer 85：282-289, 1999

24）Ikeguchi M, Oka S, Saito H, et al：Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas. Eur Surg Res 31：357-363, 1999

25）Yoshikawa T, Suzuki K, Kobayashi O, et al：Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer. Brit J Cancer 79：1145-1150, 1999

26）Saeki T, Tanada M, Takashima S, et al：Correlation between expression of platelet-derived endothelial cell growth factor（thymidine phosphorylase）and microvessel density in early-stage human colon carcinomas. Jpn J Clin Oncol 27：227-230, 1997

27）Yamamoto A, Dhar DK, El-Assal ON, et al：Thymidine phosphorylase（platelet-derived endothelial cell growth factor）, microvessel density and clinical outcome in hepatocellular carcinoma. J Hepat 29：290-299, 1998

28）Brown NS and Bicknell R：Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 334：1-8, 1998

29）Desgranges C, Razaka G, Rabaud M, et al：Catabolism of thymidine in human blood platelets：purification and properties of thymidine phosphorylase. Bioche Biophys Acta 654：211-218, 1981

30）Haraguchi M, Miyadera K, Uemura K, et al：Angiogenic activity of enzymes. Nature 368（17）：198, 1994

31）Moghaddam A, Zhang HT, Fan TPD, et al：Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92：998-1002, 1995

32）Nishino I, Spinazzola A and Hirano M：Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283（5402）：689-692, 1999

33）Morita T, Matsuzaki A and Suzuki K：Role of thymidine phosphorylase in biomodulation of fluoropyrimidines. Curr Pharm Biotechnol 2：257-267, 2001

34）Miyoshi Y, Uemura H, Ishiguro H, et al：Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis 8：260-265, 2005

35）Kataoka A, Yuasa T, Kageyama S, et al：Expression of thymidine phosphorylase correlates with microvessel density in prostate cancer. Oncol Rep 13：597-600, 2005

36）Kitazono M, Takebayashi Y, Ishitsuka K, et al：Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Comm 253：797-803, 1998

37）Ikeda R, Furukawa T and Kitazono M：Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose. Biochem Biophys Res Commun 291：806-812, 2002

38）Cohen JL, Irwin LW, Marshall OJ, et al：Clinical pharmacology of oral and intravenous 5-fluorouracil（NSC-19893）. Cancer Chemther Rep 58：723-731, 1974

39）Miwa M, Ura M, Nishida M, et al：Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34：1274-1281, 1998

40）Morita T, Matsuzaki A and Tokue A：Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 92：451-456, 2001

41）Schwartz EL, Baptiste N, Wadler S, et al：Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 270：19073-19077, 1995

42）Wadler S and Schwartz EL：Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies：a review. Cancer Res 50：3473-3486, 1990

43）Ishikawa T, Sekiguchi F, Fukase Y, et al：Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58：685-690, 1998

44）Koizumi W, Saigenji K, Nakamaru N, et al：Prediction of response to 5'-deoxy-5-fluorouridine（5'-DFUR）in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology 56：215-222, 1999

45）Fox SB, Engels K, Comley M, et al：Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 8：271-275, 1997

46）Morita T and Tokue A：Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells：relationship to the expression of thymidine phosphorylase. Cancer Chemother Pharmacol 44：91-96, 1999

47）Li G, Kawakami S, Kageyama Y, et al：IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in bladder cancer cells. Anticancer Res 22：2607-2612, 2002

48）Elias L and Sandoval JM：Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163：867-874, 1989

49）Eda H, Fujimoto K, Watanabe S, et al：Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32：333-338, 1993

50）Atzpodien J, Kirchner H, Hanninen EL, et al：Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29：S6-S8, 1993

51）Sella A, Logothetis CJ, Fitz K, et al：PhaseⅡstudy of interferon-alpha and chemotherapy（5-fluorouracil and mitomycin C）in metastatic renal cell cancer. J Urol 147：573-577, 1992

52）Haarstad H, Jacobsen AB, Schjlseth SA, et al：Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma：a phaseⅡstudy. Ann Oncol 5：245-248, 1994

53）Elias L, Blumenstein BA, Kish J, et al：A phaseⅡtrial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. Cancer 78：1085-1088, 1996

54）Gebrosky NP, Koukol S, Nseyo UO, et al：Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon. Urology 50：863-867, 1997

55）赤座英之，亀山周二，金村三樹郎，他：進行腎細胞癌に対するヒトリンパ芽球性インターフェロンα（IFN-α）とUFTの併用療法―計画的多施設共同研究．日泌尿会誌 82：1053-1058，1991

56）Padrik P, Leppik K and Arak A：Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma：a phaseⅡstudy. Urol Oncol 22：387-392, 2004

57）Swanson DA：Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma? Semin Urol 11：35-40, 1993

58）Sawada N, Ishikawa T, Fukase Y, et al：Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4：1013-1019, 1998

59）Bogdan C and Ding A：Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukocyte Biol 52：119-121, 1992

60）Ishikawa T, Tanaka Y, Ishitsuka H, et al：Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adeno-carcinoma. Jpn J Cancer Res 80：583-591, 1989

61）Sawada N, Ishikawa T, Sekiguchi F, et al：X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine（Xeloda）in human cancer xenografts. Clin Cancer Res 5：2948-2953, 1999